Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers

Velez, Gabriel; Wolf, Julian; Dufour, Antoine; Mruthyunjaya, Prithvi; Mahajan, Vinit B.

doi:10.1167/iovs.64.14.14

Cited by 2 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another advantage of analyzing AH or tears is that samples can be obtained from patients with early disease stages, such as nonproliferative DR, early AMD, or glaucoma, where a vitrectomy may not be indicated. Cross-platform comparisons can provide insights into how a single biopsy performs and what the differences are based on biopsy type. , Altogether, the current technologies make it possible to address these questions, and investigators have a menu of strategies from which to choose.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy Proteomics in Ophthalmology

Wolf,

Franco,

Yip

et al. 2024

J. Proteome Res.

Self Cite

View full text Add to dashboard Cite

Minimally invasive liquid biopsies from the eye capture locally enriched fluids that contain thousands of proteins from highly specialized ocular cell types, presenting a promising alternative to solid tissue biopsies. The advantages of liquid biopsies include sampling the eye without causing irreversible functional damage, potentially better reflecting tissue heterogeneity, collecting samples in an outpatient setting, monitoring therapeutic response with sequential sampling, and even allowing examination of disease mechanisms at the cell level in living humans, an approach that we refer to as TEMPO (Tracing Expression of Multiple Protein Origins). Liquid biopsy proteomics has the potential to transform molecular diagnostics and prognostics and to assess disease mechanisms and personalized therapeutic strategies in individual patients. This review addresses opportunities, challenges, and future directions of high-resolution liquid biopsy proteomics in ophthalmology, with particular emphasis on the large-scale collection of high-quality samples, cutting edge proteomics technology, and artificial intelligence-supported data analysis.

show abstract

Section: Challenges and Future Directionsmentioning

confidence: 99%

“…Cross-platform comparisons can provide insights into how a single biopsy performs and what the differences are based on biopsy type. 101 , 102 Altogether, the current technologies make it possible to address these questions, and investigators have a menu of strategies from which to choose.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Liquid Biopsy Proteomics in Ophthalmology

Wolf,

Franco,

Yip

et al. 2024

J. Proteome Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…They provided data on expression levels in UM aqueous humor samples relative to a control group, but did not establish a link with clinical aspects, such as tumor thickness and basal diameter [ 114 ]. In addition, the vitreous humor of UM patients ( n = 8) with high-risk GEP tumors showed higher expression of LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1), HGFR (hepatocyte growth factor receptor), PYGL (liver glycogen phosphorylase) and ENPP-2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) proteins in comparison to controls ( n = 3) [ 115 ]. The analysis of cytokines ( n = 32) revealed that twenty-six were differentially expressed in the vitreous humor from UM patients compared to the control group [ 116 ].…”

Section: Novel Biomarkersmentioning

confidence: 99%

“…Metabolic heterogeneity was identified within these BAP1 mutant samples, revealing two distinct metabolic phenotypes: OXPHOS high , characterized by elevated glycolysis and nucleotide biosynthesis (GLUT3 and HK1), and OXPHOS low , which relies heavily on fatty acid oxidation (CPT1A) [ 152 ]. Additionally, protein expression patterns in the vitreous humor revealed a notable prevalence of metabolic processes, including glycolysis, gluconeogenesis and amino acid biosynthesis, particularly in GEP class 2 UM cases [ 115 ]. Along with the metabolic pathways, alterations in cellular signaling were also discovered.…”

Section: Altered Molecular Mechanisms In Ummentioning

confidence: 99%

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

Fuentes-Rodriguez,

Mitchell,

Guérin

et al. 2024

Cells

View full text Add to dashboard Cite

Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis. This review highlights recent advancements in understanding the molecular pathogenesis, genetic alterations, and immune microenvironment of UM, with a focus on pivotal genes, such as GNAQ/11, BAP1, and CYSLTR2, and delves into the distinctive genetic and chromosomal classifications of UM, emphasizing the role of mutations and chromosomal rearrangements in disease progression and metastatic risk. Novel diagnostic biomarkers, including circulating tumor cells, DNA and extracellular vesicles, are discussed, offering potential non-invasive approaches for early detection and monitoring. It also explores emerging prognostic markers and their implications for patient stratification and personalized treatment strategies. Therapeutic approaches, including histone deacetylase inhibitors, MAPK pathway inhibitors, and emerging trends and concepts like CAR T-cell therapy, are evaluated for their efficacy in UM treatment. This review identifies challenges in UM research, such as the limited treatment options for metastatic UM and the need for improved prognostic tools, and suggests future directions, including the discovery of novel therapeutic targets, immunotherapeutic strategies, and advanced drug delivery systems. The review concludes by emphasizing the importance of continued research and innovation in addressing the unique challenges of UM to improve patient outcomes and develop more effective treatment strategies.

show abstract

Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers

Cited by 2 publications

References 48 publications

Liquid Biopsy Proteomics in Ophthalmology

Liquid Biopsy Proteomics in Ophthalmology

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

Contact Info

Product

Resources

About